Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells

Authors: Li Wang, JianTao Wang, Zhixi Li, YanYang Liu, Ming Jiang, Yan Li, Dan Cao, Maoyuan Zhao, Feng Wang, Feng Luo

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Stem cell factor (SCF) plays an important role in tumor growth and metastasis. However, the function of SCF in regulating stemness and migration of cancer stem cells (CSCs) remains largely undefined. Here, we report that non-adhesive culture system can enrich and expand CSCs derived from Lewis lung carcinoma (LLC) cells and that the expression level of SCF in CSCs was higher than those in LLC cells. Silencing SCF via short hairpin (sh) RNA lentivirus transduction attenuated sphere formation and inhibited expressions of stemness genes, ALDH1, Sox2, and Oct4 of CSCs in vitro and in vivo. Moreover, SCF-silenced CSCs inhibited the migration and epithelial-mesenchymal transition, with decreased expression of N-cadherin, Vimentin, and increased expression of E-cadherin in vitro and in vivo. Finally, SCF-short hairpin RNA (shRNA) lentivirus transduction suppressed tumorigenicity of CSCs. Taken together, our findings unraveled an important role of SCF in CSCs derived from LLC cells. SCF might serve as a novel target for lung cancer therapy.
Literature
1.
2.
Lundin A, Driscoll B. Lung cancer stem cells: progress and prospects. Cancer Lett. 2013;338:89–93.CrossRefPubMed
3.
Flaherty JD O, Barr M, Fennell D. The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. J Thorac Oncol. 2012;7:1880–90.CrossRef
4.
Wang L, Guo H, Lin C, et al. Enrichment and characterization of cancer stem like cells from a cervical cancer cell line. Mol Med Rep. 2014;9:2117–23.PubMedPubMedCentral
5.
Wang L, Guo H, Yang L, et al. Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-kB activity and apoptosis induction. Mol Cell Biochem. 2013;379:7–18.CrossRefPubMed
6.
Martin FH, Suggs SV, Langley KE, et al. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell. 1990;63:203–11.CrossRefPubMed
7.
Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63:213–24.CrossRefPubMed
8.
Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-kit: from basic science to clinical implications. Physiol Rev. 2012;92:1619–49.CrossRefPubMed
9.
Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345–64.PubMed
10.
Sette C, Dolci S, Geremia R, Rossi P. The role of stem cell factor and of alternative c-kit gene products in the establishment, maintenance and function of grem cells. Int J Dev Biol. 2000;44:599–608.PubMed
11.
Yoshida H, Kunisada T, Grimm T, et al. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc. 2001;6:1–5.CrossRefPubMed
12.
Kindler T, Breitenbuecher F, Marx A, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood. 2004;103:3644–54.CrossRefPubMed
13.
Wang X, Ren H, Zhao T, et al. Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 2014;35:2283–90.CrossRefPubMed
14.
Chiron D, Maiqa S, Surget S, et al. Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J. 2013;3:e120.CrossRefPubMedPubMedCentral
15.
Catalano A, Rodilossi S, Rippo MR, et al. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem. 2004;279:46706–14.CrossRefPubMed
16.
Chen SF, Chang YC, Nieh S, et al. Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PLoS One. 2012;7:e31864.CrossRefPubMedPubMedCentral
17.
Huang YC, Yang ZM, Chen XH, et al. Isolation of mesenchymal stem cells from human placental decidua basalis and resistance to hypoxia and serum deprivation. Stem Cell Rev. 2009;5:247–55.CrossRefPubMed
18.
Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT. Methods Mol Biol. 2011;731:237–45.CrossRefPubMed
19.
Allred DC, Harvev JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMed
20.
Frlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer. 2010;127:2893–917.CrossRef
21.
Mao XG, Guo G, Wang P, et al. Maintenance of critical properties of brain tumor stem-like cells after cryopreservation. Cell Mol Neurobiol. 2010;30:775–86.CrossRefPubMed
22.
Su YJ, Lai HM, Chang YW, et al. Direct reprogramming of stem cell properies in colon cancer cell by CD44. EMBO J. 2010;30:3186–99.CrossRef
23.
Zhang LL, Jiao M, Li L, et al. Tumor spheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol. 2012;138:675–86.CrossRefPubMed
24.
Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311–20.CrossRefPubMedPubMedCentral
25.
Williams A, Datar R, Cote R. Technologies and methods used for the detection, enrichment and characterization of cancer stem cells. NatI Med J India. 2010;23:346–50.
26.
Szotek PP, Pieretti VR, Masiakos PT, et al. Ovarin cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc NatI Acad Sci USA. 2006;103:11154–9.CrossRef
27.
Guo Y, Liu S, Wang P. Expression profile of embryonic stem cell associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology. 2011;59:763–75.CrossRefPubMed
28.
Oppel F, Muller N, Schackert G. Sox2-RNAi attenutates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Mol Cancer. 2011;10:137.CrossRefPubMedPubMedCentral
29.
Ikushima H, Todo T, Ino Y. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem. 2011;286:41434–41.CrossRefPubMedPubMedCentral
30.
Zhang D, Zheng L, Shi H, et al. Suppression of Peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer. Int J Med Sci. 2014;11:870–9.CrossRefPubMedPubMedCentral
31.
Li K, Li B, Gao LN, et al. Mesenchymal stem cell characteristics of dental pulp and periodontal ligament stem cells after in vivo transplantation. Biomaterials. 2014;35:6332–43.CrossRefPubMed
32.
Yi F, Khan M, Gao H, et al. Increased differentiation capacity of bone marrow-derived mesenchymal stem cells in aquaporin-5 deficiency. Stem Cells Dev. 2012;21:2495–507.CrossRefPubMedPubMedCentral
33.
Desai A, Webb B, Geson SL. CD113+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Raidother Oncol. 2014;110:538–45.CrossRef
34.
Xie ZY, Lv K, Xiong Y, Guo WH. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer. Oncol Res Treat. 2014;37(11):666–8. 670-2.CrossRefPubMed
35.
Wang F, Mi YJ, Chen XG, et al. Axitinib targeted cancer stem like cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med. 2012;18:887–98.PubMedPubMedCentral
36.
Yu L, Liu X, Cui K, et al. SND1 acts downstream of TGFB1 and upstream of Smurf1 to promote breast cancer metastasis. Cancer Res. 2015;75:1275–86.CrossRefPubMed
37.
Joseph JV, Conroy S, Pavlov K, et al. Hypoxia enhanced migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF-1a-ZEB1 axis. Cancer Lett. 2015;359:107–16.CrossRefPubMed
38.
Piao Z, Hong CS, Jung MR, et al. Thymosin B4 induces invasion and migration of human colorectal cancer cells through the ILK/AKT/B-catenin signaling pathway. Biochem Biophys Tes Commun. 2014;452:858–64.CrossRef
39.
Hollier BG, Evans K, Mani SA. The epithelial to mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009;14:29–43.CrossRefPubMed
40.
41.
42.
Cao L, Zhou Y, Zhai B, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71.CrossRefPubMedPubMedCentral
43.
Yang L, Guo H, Dong L, et al. Tanshione IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells. Oncol Rep. 2014;2:1303–11.
44.
Lin C, Wang L, Wang H, et al. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathway. J Cell Biochem. 2013;114:2061–70.CrossRefPubMed
45.
46.
Aguilar C, Aguilar C, Lopez MR, et al. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-kit expressing cervical cancer cells through the sustained activation of ERK1/2. Mol Med Rep. 2014;9:1895–902.PubMed
47.
Wiesner C, Nabha SM, Dos Santos EB, et al. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia. 2008;10:996–1003.CrossRefPubMedPubMedCentral
48.
49.
Brian Druker J, Diana Griffith J, Michael Heinrich C, et al. inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–32.
50.
Bai CG, Hou XW, Wang F, et al. Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth. World J Gastroenterol. 2012;18:2929–37.CrossRefPubMedPubMedCentral
51.
Belloc F, Airiau K, Jeanneteau M, et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia. 2009;23:679–85.CrossRefPubMed
Metadata
Title
Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells
Authors
Li Wang
JianTao Wang
Zhixi Li
YanYang Liu
Ming Jiang
Yan Li
Dan Cao
Maoyuan Zhao
Feng Wang
Feng Luo
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4577-6

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

Immunomodulatory and cellular antioxidant activities of pure compounds from Teucrium ramosissimum Desf.

Original Article

Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling

Original Article

Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis

Original Article

Solanum tuberosum lectin inhibits Ehrlich ascites carcinoma cells growth by inducing apoptosis and G2/M cell cycle arrest

Original Article

Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer

Original Article

Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits